Anagrelide-induced visual hallucinations in a patient with essential thrombocythemia [1]

European Journal of Haematology

Volumn 73, Issue 3, 2004, Pages 223-224

  Swords, R ^a   Fay, M ^a   O'Donnell, R ^a   Murphy, P T ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; HYDROXYUREA;

AGED; ANEMIA; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INOTROPISM; LETTER; PHLEBOTOMY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTHEMIA; VASODILATATION; VISUAL HALLUCINATION;

AGED; FEMALE; HALLUCINATIONS; HUMANS; PLATELET AGGREGATION INHIBITORS; QUINAZOLINES; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 4043106214     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00289.x     Document Type: Letter

References (5)

1. TEFFERI A, SILVERSTIEN MN, PETITT RM. Anagrelide as anew platelet lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost 1991;23:379-383.
2. BARBUI T, BAROSI G, GROSSI A et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Haematology, the Italian Society of Experimental Haematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89: 215-232.
3. STOREN EC, TEFFERI A. Long term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-866.
4. MAZZUCCONI MG, DE SANCTIS V, Chistolini A et al. Therapy with anagrelide in patients affected with essential thrombocythemia: preliminary results. Haematologica 1992;77:315-317.
5. PETRIDES PE, BEYKIRCH MK, TRAPP OM. Anagrelide, a novel platelet lowering option in essential thrombocythemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998;61:71-76.